MedTrace Logo

DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

NCT01733823 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-07-28

No results posted yet for this study

Summary

P16 negative cancers continue to have a dismal prognosis despite advances in the treatment of head and neck cancer. Acceleration, dose-escalation, hyperfractionation, chemotherapy and nimorazole has been shown to improve local control. The purpose of the study i to investigate the level of co-morbidity and performance status (PS) that allows the combination of all of the above means of treatment intensification

Conditions

  • HNSCC,Larynx, Pharynx and Oral Cavity

Interventions

RADIATION

76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole

Sponsors & Collaborators

  • Danish Head and Neck Cancer Group

    lead NETWORK

Principal Investigators

  • Jens Overgaard, MD, DMSc · Danish Head and Neck Cancer Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733823 on ClinicalTrials.gov